Human brain GABA levels rise rapidly after initiation of vigabatrin therapy

Neurology

Volumn 47, Issue 6, 1996, Pages 1567-1571

  Petroff, O A C ^a   Rothman, D L ^b   Behar, K L ^a   Collins, T L ^a   Mattson, R H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CARBAMAZEPINE; PHENYTOIN; PRIMIDONE; VIGABATRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; FEMALE; GABAERGIC SYSTEM; HUMAN; INTRACTABLE EPILEPSY; MALE; OCCIPITAL CORTEX; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 0029751102     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.6.1567     Document Type: Article

References (45)

1. Mumford JP, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989;27(suppl 1):101S-107S.
2. Kälviäinen R, Mervaala E, Sivensius J, Riekkinen PJ. Vigabatrin: clinical use. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York: Raven Press, 1995: 925-930.
3. Kälviäinen R, Äikiä M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. Arch Neurol 1995;52: 989-996.
4. Jung MJ, Lippert B, Metcalf BW, Böhlen P, Schechter PJ. γ-Vinyl-GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain metabolism in mice. J Neurochem 1977;29:797-802.
5. Bolton JB, Rimmer E, Williams J, Richens A. The effect of vigabatrin on brain and platelet GABA-transaminase activities. Br J Clin Pharmacol 1989;27(suppl 1):35S-42S.
6. Jung MJ, Palfreyman MG. Vigabatrin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York: Raven Press, 1995:903-913.
7. Schechter PJ, Hanke NFJ, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl-GABA in patients with epilepsy. Neurology 1984;34:182-186.
8. Halonen T, Lehtinen M, Pitkänen A, Ylinen A, Riekkinen PJ. Inhibitory and excitatory amino acids in CSF of patients suffering with complex partial seizures during chronic treatment with gamma-vinyl GABA (vigabatrin). Epilepsy Res 1988;2:246-252.
9. Reikkinen PJ, Pitkänen A, Ylinen A, Sivenius J, Halonen T. Specificity of vigabatrin for the GABAergic system in human epilepsy. Epilepsia 1989;30(suppl 3):S18-S22.
10. Ben-Menachem E, Persson LI, Schechter PJ, et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989;27(suppl 1):79S-85S.
11. Reikkinen PJ, Ylinen A, Halonen T, Sivenius J, Pitkänen A. Cerebrospinal fluid GABA and seizure control with vigabatrin. Br J Clin Pharmacol 1989;27(suppl 1):87S-94S.
12. Ben-Menachem E. Pharmacokinetic effects of vigabatrin on cerebrospinal fluid amino acids in humans. Epilepsia 1989; 30(suppl 3):S12-S14.
13. Ben-Menachem E, Persson LI, Mumford JP, Haegele KD, Huebert N. The effect of long-term vigabatrin therapy on selected neurotransmitter concentrations in cerebrospinal fluid. J Child Neurol 1991;6(suppl 2):2S11-2S16.
14. Kälviäinen R, Halonen T, Pitkänen A, Reikkinen PJ. Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: effect of vigabatrin and carbamazepine monotherapies. J Neurochem 1993;60:1244-1250.
15. Ben-Menachem E, Hamberger A, Mumford J. Effect of long-term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system: a case study. Epilepsy Res 1993;16:241-243.
16. 1H NMR measurements of GABA levels in human brain in vivo. Proc Natl Acad Sci USA 1993;90:5662-5666.
17. Petroff OAC, Pleban LA, Spencer DD. Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of epileptic human brain. Magn Reson Imag 1995;13:1197-1211.
18. Mattson RH, Petroff O, Rothman D, Behar K. Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. Epilepsia 1994;53(suppl 5):S29-S32.
19. 1H spectroscopic measurements of GABA, glutamate, and glutamine in human brain. Epilepsia 1995;36:457-464.
20. Mattson RH, Petroff OAC, Rothman DL, Behar KL. Vigabatrin: effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. Acta Neurol Scand 1995; 162(suppl):27-30.
21. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 1996; 46:1459-1463.
22. Haegle KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986;40:581-586.
23. Frisk-Holmberg M, Kerth P, Meyer Ph. Effect of food on the absorption of vigabatrin. Br J Clin Pharmac 1989;27(suppl 1):23S-25S.
24. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989;27(suppl 1):19S-22S.
25. Ben-Menachem E. Vigabatrin: chemistry, absorption, distribution, and elimination. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York: Raven Press, 1995:915-923.
26. Ben-Menachem E, Perrson LI, Schechter PJ, et al. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res 1988;2:96-101.
27. 1H NMR in human visual cortex during physiologic stimulation. Proc Natl Acad Sci USA 1991;88:5829-5831.
28. 13C]-glutamate turnover in human brain. Proc Natl Acad Sci USA 1992;89:9603-9606.
29. 13C glucose. J Neurochem 1994;63:1377-1385.
30. Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ. Simultaneous determination of the rates of the TCA cycle, glucose utilization, alpha-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab 1995;18:12-25.
31. 1H-double resonance difference spectroscopy of the rat brain in vivo. Proc Natl Acad Sci USA 1984;81:6330-6334.
32. 1H NMR spectra of human brain. Magn Reson Med 1994;32:294-302.
33. Gardner MJ, Altman DG. Statistics with confidence. London: British Medical Journal, 1989.
34. Roberts E. Failure of GABAergic inhibition: a key to local and global seizures. Adv Neurol 1986;44:319-341.
35. Meldrum BS. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Clin Pharmacol 1989;27(suppl 1):3S-11S.
36. Löscher W, Schmidt D. Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res 1994;17:95-134.
37. Löscher W, Frey HH. One to three day dose intervals during subchronic treatment of epileptic gerbils with gamma-vinyl GABA: anticonvulsant efficacy and alterations in regional brain GABA levels. Eur J Pharmacol 1987;143:335-342.
38. Löscher W, Jäckel R, Müller F. Anticonvulsant and proconvulsant effects of inhibitors of GABA degradation in the amygdala-kindling model. Eur J Pharmacol 1989;163:1-14.
39. 31P NMR spectroscopic study of rat brain in vivo. Magn Reson Med 1994;31:660-667.
40. Manor D, Rothman DL, Mason GF, Hyder F, Petroff OAC, Behar KL. GABA synthesis in the rat cortex is reduced 24 hours following inhibition of GABA transaminase [abstract]. J Neurochem 1996;66(suppl 1):S81.
41. Bernasconi R, Bittiger H, Schmutz M, Martin P, Klein M. Is the estimation of the GABA turnover rate in vivo a tool to differentiate between various types of drugs interfering with the GABA/benzodiazapine/ionophore receptor complex? Neuropharmacology 1984;23:815-816.
42. Martin SB, Martin DL. Stimulation by phosphate of the activation of glutamate apodecarboxylase by pyridoxyl-5′-phosphate and its implications for the control of GABA synthesis. J Neurochem 1979;33:1275-1283.
43. Martin DL. Regulatory properties of brain glutamate decarboxylase. Cell Mol Neurobiol 1987;7:237-253.
44. Martin DL, Rimvall K. Regulation of gamma-aminobutyric acid synthesis in the brain. J Neurochem 1993;60:395-407.
45. 67 protein is highly sensitive to small increases in intraneuronal gamma-aminobutyric acid levels. J Neurochem 1994;62:1375-1381.